Integrating Dosimetry, PK & Biodistribution to Improve Human Dose Prediction & Inform Clinical Progression

• Combining imaging-derived kinetics, PK & biodistribution data to build more robust human dose predictions
• Accounting for species differences in distribution, clearance, & organ kinetics to improve extrapolation from animals to humans
• Quantifying uncertainty in predicted tumor & organ doses to determine when estimates are reliable enough to support clinical progression

Speakers:

Charles Glaus

Senior Director, Oncology Precision Medicine, Early Clinical Development

Bayer